Skip to main content
Premium Trial:

Request an Annual Quote

The Little RNAs

MIT's Technology Review checks in with Regulus, a startup owned by both Alnylam and Isis that focuses on developing miRNA-based drugs. "The analogy we like to use is that miRNA is the maestro conducting the orchestra — the entire biological network," Regulus's Zak Zimmerman tells Tech Review."If something goes wrong with the maestro, the orchestra starts to play off-key." So far, the company has developed compounds that affect the oligonucleotides of miRNAs and is particularly interested in heart failure and renal fibrosis. However, the article adds, getting from a compound to a drug is likely to take a lot of work as miRNAs affect many processes and therapies targeting them may cause a variety of side effects.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.